Mereo BioPharma Group plc Stock price London S.E.
Equities
MPH
GB00BZ4G2K23
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- GBX | -.--% | -10.17% | -.--% |
04:19pm | European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday | MT |
01:51pm | Needham Adjusts Price Target on Mereo BioPharma to $6 From $5, Keeps Buy Rating | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 333M 420M |
---|---|---|---|---|---|
Net income 2024 * | -37M -46.76M | Net income 2025 * | -43M -54.34M | EV / Sales 2024 * | - |
Net cash position 2024 * | 69.4M 87.71M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-39.6
x | P/E ratio 2025 * |
-43.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.94% |
Latest transcript on Mereo BioPharma Group plc
Managers | Title | Age | Since |
---|---|---|---|
Founder | 53 | 15-02-28 | |
John P. Richard
FOU | Founder | 66 | 15-02-28 |
Founder | 64 | 15-07-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 19-04-22 |
Director/Board Member | - | 22-11-09 | |
Director/Board Member | 59 | 19-04-22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.25% | 108B | |
+9.82% | 104B | |
+6.38% | 23.66B | |
-11.55% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.32% | 16.19B | |
+5.03% | 13.72B | |
+34.85% | 12.22B |
- Stock
- Equities
- Stock Mereo BioPharma Group plc
- Stock Mereo BioPharma Group plc - London S.E.